Differential expression of mRNA and lncRNA in erlotinib-resistant non-small cell lung cancer cells

doi:10.3877/cma.j.issn.1674-6902.2020.03.015

Abstract

Abstract:

Objective

To identify the differential expression of mRNA and lncRNA in the erlotinib-resistant non-small cell lung cancer cells.

Methods

GSE80344 microarray datasets were selected from the Gene Expression Omnibus (GEO) database including the data from erlotinib-resistant HCC827 cells and sensitive cells. The aberrantly-expressed mRNAs and lncRNAs were analyzed by GEO2R and probe ID matching. The screening criteria were |Fold change|>1.5 and P value<0.01. The possible mechanisms of action of dysregulatory mRNAs and lncRNAs were investigated by Panther (http: //www.pantherdb.org), KEGG (http: //www.kegg.jp/), STRING (http: //string-db.org), and other databases. The candidate key mRNAs and lncRNAs obtained by screening were verified by survival analysis using the data from the TCGA database (https: //cancergenome.nih.gov/).

Results

Compared with the sensitive cells, there were 644 differentially-expressed mRNAs and 367 differentially-expressed lncRNAs in the erlotinib-resistant HCC827 cells, respectively, of which 128 mRNAs were up-regulated and 516 mRNAs were down-regulated. And 137 lncRNAs were up-regulated and 230 lncRNAs were down-regulated. These mRNAs and lncRNAs were mainly involved in the signaling pathways closely related to cancers, such as PI3K-Akt, Ras, MAPK, ECM receptor interactions, and so on. Database-based verification confirmed the screening results.

Conclusion

The screened out mRNAs and lncRNAs can provide theoretical and preliminary experimental bases for the further study on the mechanisms of EGFR-TKIs resistance of non-small cell lung cancer.

Key words: Non-small cell lung cancer, Erlotinib drug resistance, Differential expression, IncRNA analysis

Shubin Li, Hong Yu, Gengyue Zhang. Differential expression of mRNA and lncRNA in erlotinib-resistant non-small cell lung cancer cells[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2020, 13(03): 365-370.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2020.03.015

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2020/V13/I03/365

Figures/Tables 3

References 28

1	Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1): 7-30.
2	钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
3	陈艳丽，王媛媛，张　勇，等. 中晚期非小细胞肺癌患者化疗前后T淋巴细胞亚群表达差异分析及临床意义[J/CD]. 中华肺部疾病杂志(电子版), 2020, 13(1): 13-17.
4	Lin JJ, Shaw AT. Resisting Resistance: Targeted Therapies in Lung Cancer[J]. Trends cancer, 2016, 2(7): 350-364.
5	Fustaino V, Presutti D, Colombo T, et al. Characterization of epithelial-mesenchymal transition intermediate/hybrid phenotypes associated to resistance to EGFR inhibitors in non-small cell lung cancer cell lines[J]. Oncotarget, 2017, 8(61): 103340-103363.
6	Presutti D, Santini S, Cardinali B, et al. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells[J]. PloS one, 2015, 10(11): e0143333.
7	Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks[J]. Genome Res, 2003, 13(11): 2498-2504.
8	Zhang X, Sun S, Pu JK, et al. Long non-coding RNA expression profiles predict clinical phenotypes in glioma[J]. Neurobiol Dis, 2012, 48(1): 1-8.
9	Xue W, Li L, Tian X, et al. Integrated analysis profiles of long non-coding RNAs reveal potential biomarkers of drug resistance in lung cancer[J]. Oncotarget, 2017, 8(38): 62868-62879.
10	Wu Y, Yu DD, Hu Y, et al. Genome-wide profiling of long non-coding RNA expression patterns in the EGFR-TKI resistance of lung adenocarcinoma by microarray[J]. Oncol Rep, 2016, 35(6): 3371-3386.
11	Yang J, Lin J, Liu T, et al. Analysis of lncRNA expression profiles in non-small cell lung cancers (NSCLC) and their clinical subtypes[J]. Lung cancer, 2014, 85(2): 110-115.
12	Qu L, Ding J, Chen C, et al. Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA[J]. Cancer cell, 2016, 29(5): 653-668.
13	Jin W, Chen L, Cai X, et al. Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1[J]. Oncol Rep, 2017, 37(1): 273-280.
14	Cheng N, Li X, Zhao C, et al. Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer[J]. Oncol Rep, 2015, 33(2): 833-839.
15	Dey BK, Mueller AC, Dutta A. Long non-coding RNAs as emerging regulators of differentiation, development, and disease[J]. Transcription, 2014, 5(4): e944014.
16	Liu Z, Sun M, Lu K, et al. The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1/CIP1) expression[J]. PloS one, 2013, 8(10): e77293.
17	Liu J, Wan L, Lu K, et al. The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma[J]. PloS one, 2015, 10(5): e0114586.
18	Chen J, Zhang K, Song H, et al. Long noncoding RNA CCAT1 acts as an oncogene and promotes chemoresistance in docetaxel-resistant lung adenocarcinoma cells[J]. Oncotarget, 2016, 7(38): 62474-62489.
19	Ma P, Zhang M, Nie F, et al. Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer[J]. Biomed Pharmacother, 2017, 87: 20-26.
20	Xia L, Huang W, Tian D, et al. Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma[J]. Hepatology (Baltimore, Md), 2013, 57(2): 610-624.
21	Cheng N, Cai W, Ren S, et al. Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer[J]. Oncotarget, 2015, 6(27): 23582-23593.
22	Pan H, Jiang T, Cheng N, et al. Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer[J]. Oncotarget, 2016, 7(31): 49948-49960.
23	Wang B, Jiang H, Wang L, et al. Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway[J]. Oncol Lett, 2017, 13(5): 3494-3500.
24	Shi X, Sun M, Liu H, et al. A critical role for the long non-coding RNA GAS5 in proliferation and apoptosis in non-small-cell lung cancer[J]. Mol Carcinog, 2015, 54(Suppl 1): E1-e12.
25	Dong S, Qu X, Li W, et al. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression[J]. J Hematol Oncol, 2015, 8: 43.
26	Byers LA, Diao L, Wang J, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance[J]. Clin Cancer Res, 2013, 19(1): 279-290.
27	Zhang Z, Lee JC, Lin L, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer[J]. Nat Genet, 2012, 44(8): 852-860.
28	Vajkoczy P, Knyazev P, Kunkel A, et al. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival[J]. Proc Natl Acad Sci U S A, 2006, 103(15): 5799-5804.

[1]	Duo Li, Zhaozhao Hao, Yanwei Chen, Yandong Nan. Correlation analysis of serum PTX3 expression and bone metastasis in non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 558-562.
[2]	Song Liu, Jinzhao Zhang, Yanyun Jia. Relationship between reduced response to pabolizumab in treatment of advanced non-small cell lung cancer and antibiotic preconditioning [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 553-557.
[3]	Xiaoyu Han, Keyu Li, Zhifei Zhao, Jianping Gao. Prognostic significance of SNHG17 overexpression for non-small cell lung cancer resection [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 543-547.
[4]	Guiping Zhang, Yonglin Qiu, Qiting Zhan, Ledong Sun. Prognostic significance of serum Ape1/Ref-1 for the radioactive lung injury in patients with advanced non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 519-523.
[5]	Mengmeng Zhao, Jie Huang, Ronghuan Yu, Baoqing Wang. Overexpression of the small GTPase Rab32 inhibits the invasive growth of non-small cell lung cancer cells [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 512-518.
[6]	Lili Bai, Yu Jiang, Liangliang Huang, Ying BAI, Min Zhang. Application of occupational therapy in postoperative rehabilitation of patients with non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(03): 411-415.
[7]	Haiyan Zhao, Haitao Jin, ying Kong, Ruiyuan He. Prognostic significance of plasma NGS-ctDNA in patients with advanced NSCLC treated with EGFR-TKIs [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(03): 385-391.
[8]	Jing Yang, Jian Fu, Yanxia Kang. Significance of plasma ctDNA T790M mutation and total metabolic tumor volume in the prognostic significance of TKIs treatment in patients with advanced EGFR mutant NSCLC [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(03): 379-384.
[9]	Zhen Wang, Lu Huang, Lianqun Lang, Lu Yue. Prognostic significance of platelet and albumin/fibrinogen ratio in second-line therapy of bevacizumab for advanced non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(01): 35-40.
[10]	Jing Li, Guoyuan Ling, Shan Jiang, Xiaoju Chen, Xiaoyun Guo. Efficacy of pemetrexed delivery via ommaya capsule implantation versus lumbar puncture in treatment of leptomeningeal metastasis of non-small cell lung cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(02): 128-132.
[11]	Yang Li, Kunliang Guo, Bicheng Zhan, Quanquan Hu, Yuzhen Dai. Clinicopathological and molecular genetic characteristics and programmed cell death 1 ligand 1 expression in SMARCA4-deficient non-small cell lung cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(12): 1309-1314.
[12]	Meisi Liang, Huimin Lan, Ting Yu, Shengqiao Li. The study of plumbagin on suppressing the proliferation of non-small cell lung cancer [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2024, 12(02): 120-125.
[13]	Zijian Li, Rui Wang, Yunpeng Zhong, Dixuan Zhang, Yunjuan Liang, Chao Yang, Jianxing He, Shuben Li. Clinical application of lung autotransplantation in thoracic malignancies [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2024, 11(03): 193-200.
[14]	Xunfu Zhang, Jinshan Ma, Yunlong Jiang, Tuoleheng Jianati, Changjian Hou, Silajiding Sawuti. Expression and clinicopathological significance of GATA3 protein in non-small cell lung cancer tissues [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2024, 11(03): 175-179.
[15]	Kuan Xu, Heng Zhao, Bo Ye. Interpretation of the surgical section of the 2024 first edition of the National Comprehensive Cancer Network (NCCN) guidelines for non-small cell lung cancer [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2024, 11(02): 79-84.

Please choose a citation manager

Content to export